Last updated: September 6, 2026
Choriogonadotropin alfa, marketed primarily as Ovidrel and Ovidrel PreFilled Syringe, is a recombinant human chorionic gonadotropin used to trigger final follicular maturation and ovulation in assisted reproduction. Its commercial profile is mature: U.S. regulatory exclusivity has expired, no widely commercialized biosimilar has displaced the product, and competition comes mainly from urinary-derived hCG products and alternative ovulation-trigger protocols. Merck does not report Ovidrel revenue separately, so its financial trajectory must be assessed through product maturity, fertility-market demand, pricing, supply position, and the performance of Merck’s broader fertility franchise.
What is choriogonadotropin alfa and how is it used?
Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin produced in genetically engineered Chinese hamster ovary cells. It acts on the luteinizing hormone/hCG receptor and is administered after controlled ovarian stimulation to induce final oocyte maturation and ovulation.
The U.S. label covers two principal uses:
- Induction of final follicular maturation and ovulation in infertile women who have undergone pituitary desensitization and appropriate follicle development with gonadotropins.
- Induction of ovulation in anovulatory or oligo-ovulatory women after adequate follicular development with follicle-stimulating hormone therapy.[1]
The standard prefilled-syringe presentation contains 250 micrograms of choriogonadotropin alfa, approximately equivalent to 6,500 international units of urinary hCG. Ovidrel is administered subcutaneously, which differentiates it from several urinary hCG products traditionally administered intramuscularly or subcutaneously depending on the product.
Key product data
| Attribute |
Choriogonadotropin alfa |
| Primary brand |
Ovidrel |
| U.S. sponsor |
EMD Serono, Inc. |
| Active ingredient |
Recombinant human chorionic gonadotropin |
| Dosage form |
Prefilled syringe and injection |
| Common dose |
250 micrograms subcutaneously |
| Therapeutic category |
Fertility treatment and ovulation induction |
| U.S. NDA |
21-343 |
| FDA approval |
2000 |
| Main clinical role |
Final follicular maturation and ovulation trigger |
| Biosimilar status |
No widely marketed U.S. biosimilar identified |
| Regulatory exclusivity |
Expired |
What is the FDA and Orange Book status of Ovidrel?
Ovidrel was approved by the FDA in 2000 under NDA 21-343. The product is an approved recombinant biologic used in reproductive medicine. Its original regulatory exclusivity periods have expired, leaving commercial protection dependent on patents, manufacturing know-how, brand recognition, physician familiarity, and supply reliability.[1]
Ovidrel is listed in FDA drug databases as a prescription fertility product. The product is not a high-growth biologic protected by current reference-product exclusivity. Its practical market protection is weaker than that of newer monoclonal antibodies and long-acting biologics because the active ingredient is established, the clinical use is well characterized, and competing hCG products have long been available.
The Orange Book is relevant because Ovidrel was approved through an NDA pathway and is a drug product subject to FDA therapeutic-equivalence listing rules. However, an absence of a broadly marketed abbreviated new drug application does not mean the product has no competition. hCG products can compete through different regulatory pathways, including separate NDAs, biologic development, or established urinary-derived products.
What patents protect choriogonadotropin alfa?
The commercial protection for choriogonadotropin alfa is now primarily historical rather than active. Early patent protection was directed to recombinant hCG production, expression systems, purification, glycosylation, and pharmaceutical formulations. The relevant patent families were filed in the 1980s and 1990s, making ordinary 20-year patent terms expire in the 2000s and 2010s, subject to patent-term adjustment or extension.
A current, commercially meaningful U.S. patent estate is not apparent from the public FDA product record and standard Orange Book listings associated with Ovidrel. No active formulation or method-of-use patent has become a major public barrier to U.S. competition in the manner seen with newer specialty biologics.[2]
Patent protection by category
| Protection category |
Current commercial relevance |
| Recombinant hCG composition and production |
Mostly expired or historical |
| Cell-line and expression technology |
Potentially relevant as manufacturing know-how, not usually a direct product barrier |
| Purification and glycosylation methods |
Can remain confidential or be protected outside the Orange Book |
| Prefilled-syringe formulation |
Limited public evidence of a current blocking estate |
| Ovulation-induction method claims |
Broad clinical-use claims are likely vulnerable to expiration or design-around |
| Trade secrets |
Potentially important in cell culture, purification, potency control, and scale-up |
| Regulatory exclusivity |
Expired |
The distinction between patent expiration and manufacturing difficulty is important. A competitor may legally manufacture hCG without infringing an expired product patent but still face quality, consistency, comparability, and supply-chain challenges.
When does choriogonadotropin alfa lose exclusivity?
Choriogonadotropin alfa lost its core U.S. regulatory exclusivity years ago. The original Ovidrel approval dates to 2000, and no current exclusivity period materially limits competition.
The product’s effective loss of exclusivity occurred in stages:
| Milestone |
Commercial effect |
| 2000 FDA approval |
Established recombinant hCG as a U.S. fertility product |
| 2000s |
Core patent and regulatory protections began to mature and expire |
| 2010s |
Ovidrel operated primarily as a mature branded product |
| 2020s |
Competition centered on hCG alternatives, fertility-clinic purchasing, and manufacturing access |
| Current market |
No meaningful reference-product exclusivity remains |
Unlike oncology or immunology biologics, Ovidrel does not have a substantial remaining exclusivity runway that would support a major valuation premium based on patent duration.
Are there biosimilar or generic challenges to Ovidrel?
No widely marketed U.S. biosimilar has displaced Ovidrel. The absence of biosimilar entry should not be interpreted as evidence of strong patent protection. The more likely explanation is that the addressable market is relatively specialized, unit volumes are lower than for major chronic biologics, and competing urinary hCG products already serve much of the same clinical need.
A biosimilar or follow-on recombinant hCG would face several technical requirements:
- Demonstration of highly similar primary and higher-order structure.
- Control of glycosylation, which affects pharmacology and clearance.
- Comparable potency in relevant bioassays.
- Consistent impurity and aggregate profiles.
- Reliable supply of a complex glycoprotein.
- Clinical or pharmacodynamic evidence sufficient for the applicable regulatory pathway.
The FDA’s biosimilar framework under the Public Health Service Act could provide a route for a follow-on product, but development economics are less attractive than for high-revenue biologics. A competitor would need to capture sufficient fertility-clinic volume while absorbing development, manufacturing, pharmacovigilance, and commercial costs.[3]
What about Paragraph IV challenges?
A Paragraph IV challenge is not publicly associated with a major current Ovidrel market disruption. Paragraph IV litigation is more relevant to small-molecule ANDA products. For recombinant hCG, a competitor may pursue a biologic or follow-on pathway rather than rely on a conventional ANDA strategy.
The practical generic-entry risk is therefore moderate rather than zero. It is constrained by market size and product complexity, not by a clearly dominant active patent estate.
What products compete with choriogonadotropin alfa?
The competitive field has three layers.
Urinary-derived hCG products
Products such as Pregnyl and Novarel compete as hCG trigger products. These products have a long clinical history and can be less differentiated on mechanism, but they differ in source material, formulation, dosing, administration, availability, and reimbursement.
Recombinant fertility products
Recombinant follicle-stimulating hormones, including follitropin alfa and follitropin beta, are not direct substitutes for the ovulation trigger but are used in the same treatment protocols. Fertility clinics often select stimulation and trigger products as a package based on protocol, contracting, patient response, and payer coverage.
Alternative trigger protocols
GnRH agonist or antagonist trigger strategies can reduce or eliminate hCG exposure in selected IVF patients, particularly where ovarian hyperstimulation syndrome risk is a concern. This creates a clinical substitution risk. Choriogonadotropin alfa remains useful when sustained luteal support or conventional trigger protocols are preferred, but its role is not immune to protocol redesign.
How strong is the patent estate for choriogonadotropin alfa?
The patent estate is weak as a current exclusivity asset and stronger as a manufacturing and execution asset.
Patent strength assessment
| Factor |
Assessment |
| Core composition claims |
Low current value because of age and likely expiration |
| Formulation claims |
Limited evidence of an active blocking position |
| Method-of-use claims |
Low to moderate, depending on jurisdiction and claim scope |
| Manufacturing patents |
Variable; trade secrets may matter more |
| Regulatory exclusivity |
None of commercial significance |
| Brand and physician familiarity |
Moderate |
| Supply reliability |
Potentially important |
| Biosimilar deterrence |
Market economics are a larger barrier than patents |
The product’s defensibility depends more on manufacturing quality, distribution, clinic relationships, and market access than on patent enforcement.
What is the financial trajectory of choriogonadotropin alfa?
Merck reports financial results by business segment and selected product categories, not by Ovidrel revenue. Public company filings therefore do not provide a reliable standalone revenue series for choriogonadotropin alfa.[4]
The financial trajectory can be characterized as mature and resilient rather than high-growth:
- Initial adoption was driven by the clinical value of recombinant, standardized hCG and subcutaneous administration.
- Revenue matured as the U.S. fertility market expanded and the product became embedded in assisted-reproduction protocols.
- Growth later became dependent on IVF cycle volumes, infertility treatment access, reimbursement, pricing, and clinic purchasing.
- The product now faces erosion pressure from urinary hCG, alternative trigger protocols, procurement discounts, and potential follow-on biologics.
- Revenue remains supported by repeat use across treatment cycles and the continuing global demand for assisted reproductive technology.
Merck’s broader Healthcare business has disclosed fertility products as part of its portfolio, but public reporting generally does not isolate Ovidrel sales. Any model assigning a precise annual revenue figure to Ovidrel without company disclosure would be speculative.
Main revenue drivers
| Driver |
Effect on Ovidrel |
| IVF and ovulation-induction volumes |
Direct positive effect |
| Fertility clinic capacity |
Positive |
| Patient self-injection preference |
Positive for prefilled syringe use |
| Reimbursement restrictions |
Negative |
| Use of GnRH agonist triggers |
Negative in selected IVF protocols |
| Urinary hCG pricing |
Negative through substitution |
| Product shortages |
Can create short-term volatility |
| Manufacturing consistency |
Supports retention and premium pricing |
| Geographic fertility access |
Determines regional growth |
What is the global market outlook?
Demand for fertility treatment is supported by delayed childbearing, infertility prevalence, expanding IVF capacity, and increased treatment access in emerging markets. Choriogonadotropin alfa is positioned to benefit from treatment-volume growth, but its product-level growth is likely to trail the broader assisted-reproduction market because it is a mature trigger product.
The strongest commercial opportunities are markets where:
- IVF infrastructure is expanding.
- Recombinant products receive reimbursement.
- Physicians favor subcutaneous administration.
- Fertility clinics use standardized stimulation protocols.
- Regulatory approval and cold-chain distribution are established.
The main geographic risks are price controls, tender-based purchasing, local urinary hCG competition, and uneven access to assisted reproduction. Europe remains strategically important to Merck’s fertility franchise, while the United States provides a high-value market with greater commercial sensitivity to insurance coverage and patient out-of-pocket costs.
What litigation and settlement agreements affect Ovidrel?
No major ongoing U.S. patent litigation or settlement agreement has become a defining commercial event for Ovidrel in the public record. The absence of prominent litigation is consistent with an old product whose principal patents have matured and whose market is not currently dominated by an active Orange Book patent dispute.
Litigation risk could arise from:
- A follow-on biologic seeking market entry.
- Manufacturing-process claims.
- Trade-secret disputes involving recombinant hCG production.
- Regulatory or labeling disputes.
- Supply or distribution agreements.
Those risks are distinct from the standard Paragraph IV litigation pattern associated with small-molecule blockbusters.
What generic launch scenarios exist?
Three scenarios are commercially plausible.
Base case
Ovidrel remains a mature branded product with stable but slow-changing demand. Urinary hCG products and alternative trigger approaches limit price increases, while fertility-cycle growth offsets moderate unit erosion.
Downside case
A credible lower-priced recombinant or follow-on hCG enters a major market, fertility clinics adopt protocol alternatives, and payers increase substitution pressure. Revenue declines faster than the underlying fertility market.
Upside case
IVF volumes expand, supply reliability improves, recombinant administration retains physician preference, and the product preserves a premium over urinary hCG. Revenue grows modestly despite its expired exclusivity.
The most likely trajectory is low-single-digit market growth at the therapeutic-category level, with Ovidrel-specific performance ranging from flat to declining depending on competitive pricing and clinic adoption. This is an analytical scenario range, not a company-reported forecast.
Key Takeaways
- Choriogonadotropin alfa is a mature recombinant hCG product marketed principally as Ovidrel.
- FDA approval dates to 2000, and meaningful regulatory exclusivity has expired.
- The current patent estate does not appear to provide a major public blocking position.
- No widely marketed U.S. biosimilar has displaced Ovidrel.
- Competitive pressure comes from Pregnyl, Novarel, other hCG products, and alternative IVF trigger protocols.
- Merck does not disclose standalone Ovidrel revenue, preventing a verified product-level revenue history.
- Commercial defensibility rests on manufacturing quality, supply, clinic relationships, formulation convenience, and physician familiarity.
- The fertility market can grow while Ovidrel revenue remains flat if substitution and pricing pressure increase.
- Generic or biosimilar entry risk is moderate, with development economics and manufacturing complexity more important than patent barriers.
FAQs about choriogonadotropin alfa
Is Ovidrel still patent protected?
Core protection associated with the original product is largely historical. No current, high-impact Orange Book patent position is publicly evident as the principal barrier to competition.
Is choriogonadotropin alfa interchangeable with Pregnyl?
The products have the same broad clinical role but are not automatically interchangeable in every regulatory or prescribing context. They differ in source, formulation, concentration, administration, and labeling.
Does Ovidrel have a biosimilar competitor?
No widely marketed U.S. biosimilar has achieved significant commercial displacement of Ovidrel.
What is the main commercial risk to Ovidrel?
The largest risks are substitution by urinary hCG, adoption of non-hCG trigger protocols, payer pressure, and entry by a lower-priced recombinant or follow-on hCG product.
Does Merck disclose Ovidrel sales?
No. Merck’s public financial reporting does not provide a dependable standalone revenue figure for Ovidrel.
References
-
U.S. Food and Drug Administration. (2000). Ovidrel (choriogonadotropin alfa) prescribing information, NDA 21-343. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. FDA.
-
Merck KGaA. (2024). Annual report 2023. Merck KGaA.
